Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
A ALIMENTARY TRACT AND METABOLISM
A02 DRUGS FOR ACID RELATED DISORDERS
A02B DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
A02BA H2-receptor antagonists
A02BA08 Lafutidine
D01131 Lafutidine (JP18/INN) <JP>
Therapeutic category of drugs in Japan [BR:br08301]
2 Agents affecting individual organs
23 Digestive organ agents
232 Peptic ulcer agents
2325 H2 blockers
D01131 Lafutidine (JP18/INN)
Drug groups [BR:br08330]
Gastrointestinal agent
DG01975 Agents for peptic ulcer
DG01481 Histamine receptor H2 antagonist
D01131 Lafutidine
Metabolizing enzyme substrate
DG01644 CYP2D6 substrate
D01131 Lafutidine
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
D01131 Lafutidine
Drug classes [BR:br08332]
Gastrointestinal agent
DG01481 Histamine receptor H2 antagonist
D01131 Lafutidine
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Histamine
HRH2
D01131 Lafutidine (JP18/INN) <JP>
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
Chemicals
D01131 Lafutidine
D01131 Lafutidine tablets
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D01131
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D01131
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D01131